CCM
KRSA

Camber Capital Management’s Korsana Biosciences, Inc. Common Stock KRSA Stock Holding History

Camber Capital Management’s Portfolio KRSA Stock Details KRSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-15,908
Closed -$27M – 32
2019
Q3 		$27M Buy
15,908
+4,751
+43% +$1.03M 1.42% 27
2019
Q2 		$17.9M Buy
+11,157
New +$3.16M 0.83% 27

Other funds holding KRSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.83B AUM 65.74% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
AWH Capital Dallas, Texas $146M AUM 71.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Camber Capital Management's KRSA Position: Q4 2019 in Review

Camber Capital Management sold out of Korsana Biosciences, Inc. Common Stock (KRSA) in Q4 2019, closing a stake of 15,908 shares — an estimated $27M sold.

Camber Capital Management first reported a position in KRSA in Q2 2019 and held it in 2 quarters. The position peaked at $27M in Q3 2019. 73 funds tracked by Wall St. Rank hold KRSA as of Q4 2019.

  • Camber Capital Management reported no remaining Korsana Biosciences, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
  • Camber Capital Management sold 15,908 Korsana Biosciences, Inc. Common Stock shares in Q4 2019, an estimated $27M.
  • Camber Capital Management first reported a position in Korsana Biosciences, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Camber Capital Management's Korsana Biosciences, Inc. Common Stock position peaked at $27M in Q3 2019.
  • 73 funds tracked by Wall St. Rank held Korsana Biosciences, Inc. Common Stock as of Q4 2019.

Based on Camber Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.